Evidence map›Paper›PMID 35832578›Full record

ArticleFrontiers in pediatrics2022

Case Report: Aicardi-Goutières Syndrome Type 6 and Dyschromatosis Symmetrica Hereditaria With Congenital Heart Disease and Mitral Valve Calcification - Phenotypic Variants Caused by Adenosine Deaminase Acting on the RNA 1 Gene Homozygous Mutations.

Lingjuan Liu, Lu Zhang, Peng Huang, Jie Xiong, Yangyang Xiao, Cheng Wang, Dingan Mao, Liqun Liu

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. The role of ADAR1 in human pathophysiology.Frontiers in cell and developmental biology · 2025
    Review
  2. Article
  3. Review
  4. RNA binding proteins in cardiovascular development and disease.Current topics in developmental biology · 2024
    Article
  5. Article
  6. Review
  7. BMJ case reports · 2023
    Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Lingjuan LiuDepartment of Pediatrics, The Second Xiangya Hospital of Central South University, Changsha, China.
Lu ZhangDepartment of Pediatrics, The Second Xiangya Hospital of Central South University, Changsha, China.
Peng HuangDepartment of Pediatrics, The Second Xiangya Hospital of Central South University, Changsha, China.
Jie XiongDepartment of Pediatrics, The Second Xiangya Hospital of Central South University, Changsha, China.
Yangyang XiaoDepartment of Pediatrics, The Second Xiangya Hospital of Central South University, Changsha, China.
Cheng WangDepartment of Pediatrics, The Second Xiangya Hospital of Central South University, Changsha, China.
Dingan MaoDepartment of Pediatrics, The Second Xiangya Hospital of Central South University, Changsha, China.
Liqun LiuDepartment of Pediatrics, The Second Xiangya Hospital of Central South University, Changsha, China.
Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dyschromatosis symmetrica hereditaria (DSH), characterized by a mixture of hyper- and hypopigmented macules on the skin, is a rare pigmentary dermatosis of autosomal dominant inheritance. The pathogenic gene is adenosine deaminase acting on the RNA 1 gene (ADAR1), mutations in this gene also lead to Aicardi-Goutières syndrome type 6 (AGS 6), a rare hereditary encephalopathy with isolated spastic paraplegia. The pathomechanism of the ADAR1 gene mutations inducing DSH has not been clarified yet. We report the first case of DSH combined with AGS caused by the homozygous mutation of the ADAR1 gene in China (c.1622T > A) and reviewed the relevant literature. AGS 6 could occur in both men and women, and start in infancy. The main characteristics are growth retardation, skin depigmentation, intracranial calcification, and cerebral white matter lesions. In the current paper, the proband also had patent ductus arteriosus (PDA), ventricular septal defect (VSD), and mitral valve calcification, which are new symptoms that have not been reported in other cases. Additionally, we also aim to discuss the possible molecular mechanisms underlying the clinical heterogeneity caused by ADAR1 gene mutations.

Indexed as

ADAR1 homozygous mutationsAGS 6DSHmitral valve calcificationPDAVSD

Identifiers

PMID35832578
PMCPMC9272138
OpenAlexW4283587110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.